HEOR
(Health Economic Outcome Research)
HEOR is one of the essential domain within the healthcare sector, providing critical insights to inform policymakers and decision-makers. HEOR supports the development of strategies that promote more equitable, accessible, and affordable healthcare by evaluating the value and efficiency of healthcare interventions.
Scrypto Analytics comprehensive insights to support evidence-based healthcare decision-making by utilizing advanced HEOR methodologies.
Evidence Synthesis Capabilities
Our experts provide end-to-end support in both qualitative and quantitative evidence synthesis using robust and scientifically validated methodologies (PRISMA, Cochrane, ISPOR, NICE DSU).
- Protocol development for Systematic Literature Review (SLR)
- SLR, Targeted Literature Review (TLR), Scoping and Rapid Review
- Statistical Analysis Plan (SAP) development
- Feasibility assessment for the Network Meta-Analysis (NMA), and Indirect Treatment Comparison (ITC)
- Pairwise or direct meta-analysis, NMA, and ITC
- Meta-regression and sensitivity analysis
RWE
(Real-World Evidence)
RWE should be integrated throughout the development process of a drug or device, as real-world data-driven analysis is a vital component of effective product development. RWE complements HEOR by leveraging Real-World Data (RWD) to enhance clinical decision-making, strengthen evidence-based practices, and improve market access and reimbursement strategies.
Scrypto Analytics offer comprehensive insights to assist evidence-based product development strategies by utilising superior RWD research
RWE
- Protocol development of observational studies following standard guidelines
- Data analysis of observational studies
- Treatment pattern, adherence, and persistence analysis
- Endpoint selection for clinical studies, target population identification, interpretation of patient-reported outcomes (PROs) and quality of life (QoL) metrics
- Epidemiological insights to assess market potential across specific indications